

# Interleukin-18

J. Alastair Gracie, Susan E. Robertson, and Iain B. McInnes

*Centre for Rheumatic Diseases, University of Glasgow, Scotland, United Kingdom*

**Abstract:** Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses. IL-18 is expressed at sites of chronic inflammation, in autoimmune diseases, in a variety of cancers, and in the context of numerous infectious diseases. This short review will describe the basic biology of IL-18 and thereafter address its potential effector and regulatory role in several human disease states including autoimmunity and infection. IL-18, previously known as interferon- $\gamma$  (IFN- $\gamma$ )-inducing factor, was identified as an endotoxin-induced serum factor that stimulated IFN- $\gamma$  production by murine splenocytes [1]. IL-18 was cloned from a murine liver cell cDNA library generated from animals primed with heat-killed *Propionibacterium acnes* and subsequently challenged with lipopolysaccharide [2]. Nucleotide sequencing of murine IL-18 predicted a precursor polypeptide of 192 amino acids lacking a conventional signal peptide and a mature protein of 157 amino acids. Subsequent cloning of human IL-18 cDNA revealed 65% homology with murine IL-18 [3] and showed that both contain an unusual leader sequence consisting of 35 amino acids at their N terminus. *J. Leukoc. Biol.* 73: 213–224; 2003.

**Key Words:** cytokine · inflammation · autoimmunity · infectious disease · interleukin-18

## REGULATION OF INTERLEUKIN (IL)-18 GENE EXPRESSION

Little is yet understood of detailed regulation of IL-18 at the gene level. The murine IL-18 gene is composed of seven exons, of which one and two are noncoding. At least two distinct TATA-less IL-18 promoters have been identified. Promoter activity upstream of exon 2 acts constitutively, whereas an area upstream of exon 1 can be lipopolysaccharide (LPS)-activated [4]. Furthermore, as the 3' untranslated region of human IL-18 mRNA lacks AUUUA destabilization sequences, these observations likely explain the constitutive expression of IL-18 mRNA in freshly isolated human peripheral blood mononuclear cells (PBMC), murine splenic macrophages, and nonimmune cells [5]. Additional studies have identified the transcription factors interferon (IFN) consensus sequence-binding protein (ICSBP) and PU.1 as being critical for the activation of

the IL-18 promoter upstream of exons 1 and 2, respectively [6]. ICSBP and PU.1 are themselves up-regulated by IFN- $\gamma$  [7–9]. IFN- $\gamma$  stimulation of macrophages has also been shown to up-regulate IL-18 gene expression via ICSBP and activator protein-1 (AP-1) elements [10]. Nuclear factor (NF)- $\kappa$ B recognition sequences identified in the promoter region of IL-18 suggest the additional involvement of NF- $\kappa$ B in regulating IL-18 gene expression.

## IL-18 EXPRESSION AND SYNTHESIS

Commensurate with a proposed role in a variety of early inflammatory responses, IL-18 has been identified in cells of haemopoietic and nonhaemopoietic lineages. Thus, IL-18 expression has been reported in macrophages, dendritic cells (DC), Kupffer cells, keratinocytes, osteoblasts, adrenal cortex cells, intestinal epithelial cells, microglial cells, and synovial fibroblasts [11–18]. However, without the enzymatic machinery necessary for IL-18 processing, expression of IL-18 mRNA or indeed pro-IL-18 protein should not necessarily infer the capacity to contribute biologic activity. The nature of native stimuli for IL-18 expression remains under investigation but includes at least LPS and FasL [19].

IL-18, like IL-1 $\beta$ , with which it shares structural homology, is produced as a 24-kD inactive precursor lacking a signal peptide (pro-IL-18). Pro-IL-18 is cleaved after Asp35 by the endoprotease IL-1 $\beta$ -converting enzyme (ICE; caspase-1) to generate a biologically active, mature 18-kD moiety [20, 21]. The importance of caspase-1 in IL-18 processing is highlighted by the lack of IFN- $\gamma$  production by LPS-stimulated splenocytes from ICE-deficient mice [22] and protection of caspase-1-deficient mice from ischemic acute renal failure [23]. In humans, secretion of mature IL-18 by granulocyte macrophage-colony stimulating factor (GM-CSF)-treated macrophages infected with influenza or Sendai virus is abolished by caspase-1 inhibitors [24]. However, caspase-1 cleavage of pro-IL-18 is not exclusive, as recent reports indicate that proteinase 3 can also generate biological activity from pro-IL-18 [25]. In contrast, cleavage of pro-IL-18 or mature IL-18 at Asp71-Ser72 and Asp76-Asn77 by caspase-3 results in the generation of biologically inactive peptides [26]. We have recently observed that culture supernatants generated from human neutrophils cleave recombinant pro- and mature IL-18 into a number of

---

Correspondence: Centre for Rheumatic Diseases, University of Glasgow, 10 Alexandra Parade, Glasgow G31 2ER. E-mail: [i.b.mcinnnes@clinmed.gla.ac.uk](mailto:i.b.mcinnnes@clinmed.gla.ac.uk)  
Received June 19, 2002; revised August 12, 2002; accepted August 14, 2002. doi: 10.1189/jlb.0602313

distinct moieties (unpublished data). We identified that this activity resides in the serine proteases elastase and cathepsin G. The biological significance of the latter remains unclear but raises the fascinating possibility that neutrophil activation during early responses may critically regulate the capacity of IL-18 to contribute to the phenotype of subsequent adaptive immune responses.

## IL-18 RECEPTOR (IL-18R) AND SIGNALING

Like that of IL-1, the IL-18R complex is a heterodimer containing an  $\alpha$  (IL-1R $\alpha$ ) chain responsible for extracellular binding of IL-18 and a nonbinding, signal-transducing  $\beta$  (AcPL) chain [27–29]. Both chains are required for functional IL-18 signaling [30]. IL-18R is expressed on a variety of cells including macrophages, neutrophils, natural killer (NK) cells, endothelial, and smooth muscle cells [31–34]. The IL-18R complex can be up-regulated on naïve T cells, T helper cell type 1 (Th1) cells, and B cells by IL-12 [28, 35]. IL-18R $\alpha$  retention on the membrane of mature Th1 cells serves as a marker for the latter in humans and murine systems [36]. In contrast, T cell receptor (TCR) ligation in the presence of IL-4 results in down-regulation of the IL-18R [37]. Modulation of this complex is therefore likely to be functionally significant. Consistent with this, administration of anti-IL-18R $\alpha$  antibody in vivo results in reduced LPS-induced mortality associated with a subsequent shift in balance from a Th1 to a Th2 immune response [36].

Upon binding of IL-18 to IL-18R $\alpha$ , IL-18R $\beta$  is recruited to form a high-affinity complex-inducing signaling pathways shared with other IL-1R family members. These involve recruitment of myeloid differentiation 88 and IL-1R-associated kinase (IRAK) to the receptor complex and their activation [38–40]. Thus, IL-18 shares downstream effector pathways with critical immune regulatory molecules such as Toll-like receptors, which are in turn implicated in regulating IL-18 expression [41, 42]. The signaling machinery therefore provides for numerous regulatory feedback loops, even at the single-cell level. Following activation, IRAK autophosphorylates, dissociates from the receptor complex, and interacts with the adaptor protein tumor necrosis factor receptor-associated factor 6 (TRAF6) [43, 44]. Phosphorylation of NF- $\kappa$ B-inducing kinase and rapid induction of I $\kappa$ B $\alpha$  degradation allow NF- $\kappa$ B nuclear translocation [45, 46]. Recently, dominant-negative transfectants of I $\kappa$ B $\alpha$  have been shown to inhibit IL-18-dependent I $\kappa$ B $\alpha$  degradation, NF- $\kappa$ B activation, and IFN- $\gamma$  expression by KG-1 cells [47]. In addition to IRAK/TRAF6 signaling, recent evidence suggests a role for mitogen-activated protein kinases (MAPK) in IL-18 signaling. Thus, activation of the MAPK p38, extracellular signal-regulated kinases (ERK) p44<sup>erk-1</sup> and p42<sup>erk-2</sup> by IL-18, was detected in a human NK cell line [48]. In Th1-type cells, IL-18 has also been shown to induce expression of GADD45 $\beta$ , which in turn binds MAPK-ERK kinase 4 (MEKK4). GADD45 $\beta$  also activated the MAPK p38. Moreover, GADD45 $\beta$  expression in naïve T cells results in selectively increasing cytokine but not TCR-induced IFN- $\gamma$  production that could be abrogated by kinase-inactive MEKK4 or p38 inhibitors [49]. However, the ability of MEKK4 to

activate p38 requires further clarification [50, 51]. In addition to IL-18-induced MAPK signaling, diminished NK cell activity and IFN- $\gamma$  production by mice deficient in the transcription factor tyk-2 in response to IL-18 suggest that like IL-12, IL-18 may also signal via tyk-2 [52]. Cooperation between IL-12 and IL-18 signaling pathways extends further, as IL-12-induced signal transducer and activator of transcription-4 has been shown to enhance IL-18-induced AP-1 binding to and activation of the IFN- $\gamma$  promoter [53, 54]. Recently, use of phosphatidylinositol-3 kinase and NF- $\kappa$ B inhibitors suggested that both were required for IL-18 induction of vascular cell adhesion molecule-1 (VCAM-1) on synovial fibroblasts [55]. Further studies in which the expression of IL-18R is systematically examined for correlation with IL-18-dependent signaling are ongoing in several laboratories.

## FUNCTIONAL EFFECTS OF IL-18

Although originally identified as a factor capable of inducing IFN- $\gamma$  production by murine splenocytes, the effector role of IL-18 is rapidly expanding. Consistent effects on lymphoid series, particularly Th1 lineage in combination with IL-12, have emerged [2]. Thus, IL-18 enhances T and NK cell maturation, cytokine production, and cytotoxicity [2, 35, 56, 57]. IL-18 also increases FasL on NK cells and consequent Fas-FasL-mediated cytotoxicity [58, 59]. IL-18-deficient mice have reduced NK cell cytolytic ability that can be restored by exogenous IL-18 [60]. However, together with IL-2, IL-18 coinduces IL-13 in murine T and NK cells and in the presence of TCR activation, induces T cell IL-4, IL-10, IL-13, and IFN- $\gamma$  production [61, 62]. In isolation, IL-18 induces high immunoglobulin E expression by B cells and in combination with IL-2, anti-CD3, and anti-CD28, markedly enhances IL-4 production by CD4<sup>+</sup> T cells [63]. When cultured alone or in combination with IL-4, IL-18 is known to induce murine T cell Th2 differentiation. This however is dependent on genetic influences, as spleen cells from BALB/c and C56BL/6 strains of mice stimulated with anti-CD3 and IL-18 exhibit enhanced Th2 and Th1 responses, respectively [64]. Thus, IL-18 can promote Th1 or Th2 lineage maturation dependent on underlying genetic influences and the ambient cytokine milieu.

On non-T cell populations, IL-18, in conjunction with IL-3, induces IL-4 and IL-13 production by bone marrow-derived basophils [65]. Direct effects on macrophages and DC have also been observed. Stimulation of bone marrow-derived macrophages or splenic DC with IL-12 and IL-18 can induce IFN- $\gamma$  production [66, 67]. Studies of knockout mice also reveal that IL-18 stimulation of peritoneal macrophages induces IL-6 production, independent of the intermediate induction of endogenous cytokines such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) or IL-1 $\beta$  [68]. Macrophages derived from rheumatoid arthritis (RA) synovial membrane but not peripheral blood monocytes respond directly to IL-18 with TNF- $\alpha$  production. Similarly, IL-18 promotes neutrophil activation, reactive oxygen intermediate synthesis, cytokine release, and degranulation [18, 31]. Recent studies suggest that IL-18 up-regulates intracellular adhesion molecule-1 (ICAM-1) and VCAM-1 expression on endothelial cells and synovial fibroblasts [55].

TABLE 1.

Knockout	Effect	Reference
IL-18	Increased susceptibility to:	
	<i>Leishmania major</i> infection	[85, 86]
	<i>Cryptococcus neoforms</i> infection	[87]
	<i>Streptococcus pneumoniae</i> infection	[88]
	<i>Plasmodium berghei</i> infection	[89]
	<i>Mycobacterial</i> infection	[90]
	Increased severity of septic arthritis	[85]
	Increased LPS-induced endotoxic shock in <i>P. acnes</i> -primed mice	[91]
	Reduced:	
	Septicaemia following <i>Staphylococcus aureus</i> infection	[85]
	Collagen-induced arthritis (CIA)	[92]
	2,4,6-T-nitrobenzene sulfonic acid (TNBS)-induced colitis	[93]
	IFN- $\gamma$ in response to <i>L. monocytogenes</i> stimulation	[94]
	Severity of autoimmune encephalomyelitis	[95]
	LPS-induced shock	[96]
	Increased resistance to:	
<i>T. Muris</i> infection	[97]	
LPS-induced liver injury in <i>P. acnes</i> primed mice	[91]	
Impaired:		
Microglial activation after influenza A infection	[98]	
Th1 response	[60]	
IFN- $\gamma$ response to <i>Mycobacterium tuberculosis</i> infection	[99]	
IL-18R	Defective NK activity, reduced IFN- $\gamma$ production, impaired Th1 development	[28]

However, other nonhaemopoietic cell responses to IL-18 are likely with direct effects on chondrocytes and cartilage matrix degradation having been reported [69]. IL-18 has further been shown to inhibit osteoclast formation via T cell GM-CSF production [70]. Keratinocytes, traditionally thought to produce but not process IL-18 [71], have now been shown to secrete biologically active IL-18 when treated with dinitrochlorobenzene and proinflammatory mediators such as LPS [72]. In addition to keratinocytes, Langerhans cells (LC) also produce IL-18 [12], which in turn contributes to the regulation of LC migration [73].

## NATURAL ANTAGONISTS TO IL-18

The discovery, cloning, and characterization of IL-18-binding protein (IL-18BP), a constitutively secreted protein able to bind IL-18 with high-affinity, provide a potential mechanism whereby IL-18 activity could be regulated. Indeed, IL-18BP inhibits IL-18-induced IFN- $\gamma$  and IL-8 production and NF- $\kappa$ B activation in vitro and LPS-induced IFN- $\gamma$  production in vivo [74, 75]. Via inhibition of IL-18-induced IFN- $\gamma$  production, recombinant IL-18BP has also been shown to augment PBMC prostaglandin production [76]. Recent studies have shown that IL-18BP expression itself may be augmented by IFN- $\gamma$  [77] and is up-regulated in sepsis [78], endothelial cells, and macrophages during active Crohn's disease (CD) [79], suggesting the existence of an endogenous, IFN- $\gamma$ -regulated feedback loop. Local levels of free IL-18 or IL-18 complexed with IL-18BP are therefore likely vital in determining net IL-18 biological activity. Generated as a result of alternative mRNA splicing, four human and two murine IL-18BP isoforms have been identified. Human IL-18BP<sub>a</sub> and IL-18BP<sub>c</sub> and murine

IL-18BP<sub>c</sub> and IL-18BP<sub>d</sub> isoforms are capable of binding to and neutralizing IL-18 [80]. In addition to IL-18BP, a homologous protein p13 encoded by the *ectromelia poxvirus* has been shown to bind to and inhibit human IL-18 activity in vitro [81]. *Molluscum contagiosum* viral proteins MC53 and MC54 inhibit IL-18-induced IFN- $\gamma$  production and NK cell activity in a similar manner as IL-18BP [82]. The recent discovery of IL-1H, a protein with sequence homology to IL-1ra, which is able to bind the IL-18R but not IL-1R [83], suggests the possible existence of another IL-18R antagonist, although functional data are awaited.

## IL-18 AND HOST DEFENSE

IL-18 possesses broad and potent immunomodulatory properties. It is unsurprising therefore that it appears essential to host defences against a variety of infections. First identified in the livers of mice infected with *Propionibacterium acnes* and LPS [84], IL-18 is particularly effective during the clearance of intracellular bacteria, fungi, and protozoa, requiring the induction of host-derived IFN- $\gamma$ , which in turn evokes effector pathways involving molecules such as nitric oxide (NO). IL-18 also plays a part in the clearance of viruses, partly through the induction of cytotoxic T cells with viral clearance being impaired in IL-18-deficient mice. Key effects of IL-18 or IL-18R deficiency are summarized in **Table 1**.

### Bacterial infections

The intracellular pathogen *Mycobacterium avium* has been widely studied using a variety of murine strains including IL-18 and IL-18R-deficient mice. These studies show the requirement for a strong Th1 response and a critical role for

TABLE 2.

	Bacterial	Viral	Fungal	Protozoan
Potentially protective	<i>M. avium</i> [60, 90, 100] <i>M. tuberculosis</i> [101] <i>Mycobacterium leprae</i> [103, 120] <i>Salmonella typhimurium</i> [104] <i>Yersinia enterocolitica</i> [105] <i>Chlamydiae trachomatis</i> [106] <i>Shigella flexneri</i> [107] <i>P. acnes</i> [84]	HSV [108] Vaccinia [109] Murine adenovirus [122] Murine cytomegalovirus [122, 123] HPV [110] HIV [112, 113] FLV [114] Epstein-Barr virus [124] <i>Ectromelia</i> [81] <i>Rubella</i> [125] <i>Influenza A</i> [98, 126] <i>Encephalomyocarditis virus</i> [127]	<i>Cryptococcus neoformans</i> [87, 130, 131] <i>Aspergillus fumigates</i> [132, 133]	<i>L. major</i> [85, 86, 134] <i>Trypanosoma cruzi</i> [135, 136] <i>Plasmodium</i> [89, 137, 138]
Potentially harmful	<i>M. tuberculosis</i> [102, 121] <i>M. leprae</i> [65]	HIV [111, 128] <i>Ebola</i> [129]		

IL-18 in expulsion of the pathogen [60, 90, 100]. The contribution of IL-18 during a protective Th1 response is further demonstrated in human studies on patients with *M. tuberculosis* infection who displayed a decreased ability to produce IL-18 and IFN- $\gamma$  in response to antigen compared with healthy PPD-responsive controls [101]. Similarly, Kinjo and colleagues [99] have recently demonstrated impaired IFN- $\gamma$  production in IL-18-deficient mice following infection. However, patients with advanced disease appear to have raised plasma IL-18 levels [102]. In leprosy, the Th1/Th2 balance is key to disease outcome, but currently data on IL-18 are conflicting. In resistant tuberculoid leprosy (TL), protective IFN- $\gamma$  production is associated with increased IL-18 mRNA expression within lesions, and monocytes from TL patients show increased IL-18 mRNA expression following in vitro challenge with bacterial antigen [103]. Furthermore, such in vitro challenge of T and NK cells of TL patients resulted in increased IFN- $\gamma$  production compared with cells from patients with susceptible lepromatous leprosy (LL). However Yoshimoto et al. [65] have shown that serum IL-18 levels were much higher in an LL cohort. IL-18 could therefore promote the development of the Th2 response, characteristic of LL. Further in vivo studies have shown the importance of IL-18 in the protective immune response to a number of bacterial infections including *salmonella*, *yersinia*, *chlamydiae*, and *shigella* [104–107].

### Viral infections

In addition to inducing IFN- $\gamma$ , IL-18 activates CD8<sup>+</sup> T cells crucial for viral clearance. IL-18 is protective in a murine model of Herpes simplex virus (HSV) infection [108]. Exogenous administration of IL-18 before infection results in up-regulated IFN- $\gamma$ -dependent NO production, leading to improved survival. In an in vivo model of *vaccinia* infection, IL-18 administration reduces pock formation [109]. Clearance of neurovirulent influenza A-infected neurons by microglial/macrophage cells is impaired in the brains of IL-18-deficient mice [98]. Down-modulation of IL-18-induced immune responses by human papilloma virus (HPV) oncoproteins may

contribute to viral pathogenesis or carcinogenesis. This may arise via HPV binding to the IL-18R, thus preventing IL-18 induction of IFN- $\gamma$  [110].

Although an early report suggested that IL-18 increased human immunodeficiency virus (HIV)-1 production in a chronically infected monocytic cell line [111], recent studies predict a protective role with IL-18 inhibiting HIV-1 production by peripheral blood cells [112]. In vaccine studies, the coinjection of DNA encoding IL-18 modulates the specific immune response toward a protective Th1 type [113]. Similarly, feline leukemia virus (FLV) DNA vaccine efficacy is enhanced by coadministration with IL-18 expression vectors [114].

Finally, immunomicroarray analysis reveals that T cells infected with HHV-6 respond by inducing a type 1 immune response. Thus, IL-18 production may play a significant role in the development and progression of diseases associated with HHV-6, including pediatric, hematologic, transplant, and neurologic disorders [115]. In contrast, in vitro HHV-6 infection of LPS-treated PBMC down-regulated IL-18 production, suggesting that the down-regulation of a cytokine involved in the induction of antiviral IFN- $\gamma$  is a strategy used by the virus to evade a host response [116].

In a murine model of viral myocarditis, there was a reduction in heart weight/body weight ratio in IL-18-treated mice and TNF- $\alpha$  mRNA expression in myocardium [117]. IL-18 reduced severity of viral myocarditis by inducing cardiac expression of IFN- $\gamma$  and increasing NK activity [118]. In a coxsackie myocarditis model, the proinflammatory response involving IL-18 contributes to pathology seen in connective tissues in the chronic stages of disease [119]. Other viral syndromes in which IL-18 is documented are shown in **Table 2**.

### Fungal infections

IL-18 in synergy with IL-12 promotes the antifungal response to *C. neoformans* by inducing IFN- $\gamma$  from NK cells and NO from macrophages [130, 139]. Thus, IL-18 administration during *C. neoformans* infection results in an increase in IFN- $\gamma$  by NK and T cells with a down-regulation of IL-4 production [130,

139, 140]. IL-18 appears effective even in the absence of IL-12 [87].

In a chronic fungal asthma model, IL-18 promotes innate responses, preventing the development of severe fungus-induced asthmatic disease [132]. In caspase-1-deficient mice, IL-18 restores defective Th1 responses during *Candida albicans* infection [133].

## Protozoan infections

Murine models suggest that susceptibility and resistance to infection with *L. major* depend on the production of IL-4 and IFN- $\gamma$ , respectively [141, 142]. Several groups have reported the protective role of IL-18 during infection. Using IL-18-deficient mice, Wei and colleagues [85] reported increased susceptibility. Neither IL-12 nor IL-18 alone induced wound healing, whereas in synergy, footpad swelling was inhibited through a NO-dependent pathway, and mice were protected from further reinfection [86]. Neutralizing anti-IL-18 antibody treatment markedly reduced protection. It is interesting that although IL-18-deficient mice on a resistant background do develop larger lesions during early disease, compared with wild-type littermates, this eventually resolves [86, 134]. Therefore, although IL-18 appears to control early disease, it is not obligate for host immunity and the required development of a Th1 phenotype [86, 134]. Protection from *T. muris* infection is associated with a strong Th2 response. IL-18-deficient mice are resistant to chronic nematode infection, and administration of exogenous IL-18 to normally resistant strains results in chronic disease. IL-18 directly suppresses the antigen-specific IL-13- and IL-4-protective response, independent of IFN- $\gamma$  production [97].

In severe combined immunodeficiency (SCID) mice, IL-18 augments NK cell-mediated immunity to *Toxoplasma gondii* [143]. Similarly, IL-18 promotes healing in IL-12-deficient mice, which have reduced capacity a priori to produce IFN- $\gamma$  [144]. In contrast, extensive liver damage and lymphoid degeneration during lethal infection with high virulence strains associated with a strong Th1-type response are reported. High levels of serum IL-18 are detected, and neutralizing anti-IL-18 antibodies can increase survival times [145]. Resistance to *T. cruzi* requires the development of a successful IFN- $\gamma$  response, which correlates with increased expression of IL-12 and IL-18 [135]. Finally, high levels of IL-18 are detected in mice infected with *P. berghei*, and neutralizing anti-IL-18 antibodies shortens survival times [137]. IL-18 is also implicated in host defense by inducing IFN- $\gamma$  production during blood-borne stages of disease [89]. Serum IL-18 rises in patients with uncomplicated *Plasmodium falciparum* malaria who mount an effective Th1 response [138].

## IL-18 IN AUTOIMMUNE AND INFLAMMATORY DISEASES

IL-18 expression and effector function has now been described in inflammatory diseases across a broad range of tissues. We have focused on recent key examples of a proinflammatory role for IL-18. Activities in additional disease states, including a

role in cancer, have been discussed recently elsewhere [19, 146].

## Inflammatory arthritis

IL-18 is present in synovial membrane of patients with RA [18, 147, 148] and with psoriatic arthritis (unpublished observations). Pro-IL-18 (24-kD) predominates, although mature IL-18 is consistently detected. IL-18 expression is localized in CD14<sup>+</sup> and CD68<sup>+</sup> macrophages and in fibroblast-like synoviocytes (FLS) in situ. IL-18R ( $\alpha$  and  $\beta$ ) chains are detected ex vivo, on up to 40% of synovial CD3<sup>+</sup> lymphocytes and on 20% of synovial CD14<sup>+</sup> macrophages and in vitro on FLS. IL-18BP may also be present in substantial concentrations [149–151]. These data clearly indicate that IL-18 and its receptor system are present in inflammatory synovitis. Its functional activities include promotion of cytokine release (particularly TNF- $\alpha$ , GM-CSF, and IFN- $\gamma$ ). Marked synergy with IL-12 and IL-15 is observed in this respect. IL-18 acts not only through lymphocyte activation but also through direct effects on macrophages. IL-18 expression is in turn up-regulated in FLS by IL-1 $\beta$  and TNF- $\alpha$ , suggesting the existence of positive feedback loops linking monokine predominance in RA with innate cytokine production and Th/c1 cell activation in synovial immune responses. IL-18 induces NO release by RA SM in vitro, which as NO inhibits caspase-1 activity, provides a further potential regulatory loop. IL-18 possesses prodegradative effects in articular cartilage. IL-18 reduces chondrocyte proliferation; up-regulates inducible NO synthase, stromelysin, and cyclooxygenase-2 (COX-2) expression; and increases glycosaminoglycan release in vitro. Such activities may be IL-1 $\beta$ -independent, although contradictory data have also emerged [152]. IL-18 further promotes synovial chemokine synthesis and angiogenesis [153, 154]. Finally, IL-18 effects are not necessarily detrimental. IL-18 inhibits osteoclast maturation through GM-CSF production by T cells, thereby retarding bone erosion [70]. Suppression of COX expression may also be mediated through IFN- $\gamma$  production with consequent effects on prostanoid-mediated local inflammation.

IL-18 has been targeted in several arthritis models in vivo. Upon challenge with type II collagen (CII) in complete Freund's adjuvant (CFA), IL-18-deficient mice on a DBA/1 background exhibit reduced incidence and severity of arthritis. Ex vivo analysis determined both cellular and humoral responses to CII were suppressed [92, 155]. Moreover, administration of recombinant IL-18 can replace the requirement for CFA in CII-induced erosive arthritis in DBA/1 mice [155]. Neutralization of IL-18 in vivo using specific antibodies or IL-18BP effectively reduces developing and established rodent arthritis in streptococcal cell wall and CIA models [152, 156]. Such effects may operate independent of IFN- $\gamma$  [152]. A feature of both models is suppression, not only of inflammation but also of matrix destruction. These data strongly suggest that the net effect of IL-18 expression is proinflammatory, at least in the context of antigen-driven, articular inflammation. Clinical studies to test this hypothesis in RA are awaited.

## Insulin-dependent Diabetes Mellitus (IDDM)

Nonobese diabetic (NOD) mice, which spontaneously develop insulinitis as a result of  $\beta$ -islet destruction, are a useful model for

human IDDM. IL-18 mRNA is up-regulated in NOD mice treated with the diabetes-inducing agent cyclophosphamide, and the murine IL-18 gene maps to the *Idd2*-susceptibility locus, suggesting a potential role in the predisposition to IDDM [157]. In a transgenic NOD model where the TCR from CD4<sup>+</sup> diabetogenic T cells is overexpressed, IL-18 as well as IL-12 and TNF- $\alpha$  levels are raised [158]. Surprisingly, however, the administration of exogenous IL-18 to diabetes-susceptible mice delayed the onset of disease, presumably by interfering with the Th1/Th2-immune balance within the pancreas [159]. The future development of IL-18-deficient NOD mice should help clarify these issues. In support of a pathogenic role for IL-18 in human disease, IL-18 serum levels are increased during the early subclinical stages of IDDM [160].

## Multiple Sclerosis (MS)

MS is characterized by myelin sheath inflammation, demyelination, and impaired nerve function [161]. Experimental autoimmune encephalomyelitis (EAE) is a murine model of MS in which the induction of myelin basic protein (MBP)-specific CD4<sup>+</sup> T cells secreting cytokines, particularly IFN- $\gamma$  and TNF- $\alpha$ , results in limb paralysis. There is evidence for IL-18 involvement in the disease process. High levels of IL-18 mRNA are found in the brains and spinal columns of EAE rats at onset and during the disease [162, 163]. In an alternate model of autoimmune encephalomyelitis, IL-18-deficient mice mount a defective, autoreactive Th1 response and are resistant to disease [95]. Up-regulation of the IL-12R by IL-18 results in enhanced IFN- $\gamma$  production and exacerbated disease. In further support of IL-18 involvement in MS, administration of a neutralizing anti-IL-18 antibody partially protects animals from disease and reduces the Th1-dominant anti-MBP T cell response [162]. Furthermore, the brains taken from patients with demyelinating MS exhibit up-regulation of IL-18 and IFN- $\gamma$  mRNA with the accompanying accumulation of Th1-specific T cells [164]. Finally, caspase-1-deficient mice exhibit decreased disease severity, and cells taken from MS patients have elevated caspase-1 levels [165, 166].

## Gastrointestinal system

Parallels exist between effector mechanisms in inflammatory bowel disease (IBD) and RA. Elevated IL-18 expression is reported in IBD, particularly CD [16, 167–169]. Thus, IL-18 is present in serum of CD patients, and bioactive IL-18 is detected in CD mucosal biopsies. Moreover, in mucosal explant cultures, IL-18 antisense suppresses IFN- $\gamma$  expression, indicating a direct relationship between IL-18 expression and Th1 effector function [167]. IL-18BP isoforms are similarly up-regulated in CD mucosa in epithelial cells and macrophages, and IL-18/IL-18BP complexes are detected in tissues together with free, mature IL-18 [79].

In vivo model systems indicate that in vitro observations are of importance. Studies using several gene-targeted murine strains suggested that IL-18 promotes colonic inflammation via IFN- $\gamma$ -dependent but NO-, Fas-L-, and TNF- $\alpha$ -independent pathways [170]. ICE-deficient mice exhibit reduced severity of dextran sulfate (DS)-induced colitis associated with reduced IL-18 expression [171]. DS colitis is ameliorated by anti-IL-18

antibody [172] or by IL-18BP:Fc protein [173]. The latter effectively suppresses DSS colitis in vivo associated with a reduction in mucosal cytokine, chemokine, and metalloproteinase gene expression [173]. Similarly, colitis is associated with increased, local IL-18 expression [168], and IL-18-deficient mice fail to develop disease [93]. IL-12p40-deficient mice develop increased severity of TNBS-induced colitis associated with enhanced IL-18 expression, suggesting interactions between IL-12 and IL-18 in colonic mucosa [174]. Finally, transfer of CD62L<sup>+</sup> CD4<sup>+</sup> T cells into SCID mice induces CD-like mucosal inflammation associated with high IL-18 expression. Administration of adenovirus containing IL-18 antisense effectively reduces inflammation in this model [175]. Together, these data strongly implicate IL-18 as an important mediator of gastrointestinal inflammation.

## Pulmonary disease

A prominent role in pulmonary inflammation is suggested by studies in human tissues and in rodent models. The effects of IL-18 in airway inflammation are not easily predicted, as it can promote Th1 and Th2 responses. In general, it appears that IL-18 is primarily a negative regulator of Th2-mediated airways hyper-reactivity (AHR) but can promote pulmonary granuloma formation and subsequent lung parenchymal damage. Thus, IL-18 expression is enhanced in pulmonary infiltrates in sarcoidosis patients [176], whereas reduced levels are found in asthmatic subjects [177]. IL-18 is detected at significantly reduced levels in bronchoalveolar lavage fluid and in alveolar macrophage cultures derived from asthmatic donors compared with healthy controls. IL-18-deficient mice challenged with ovalbumin exhibit marked eosinophilia together with exaggerated lung damage compared with controls. IL-18 administration reverses such effects [178]. In the same model, IL-12 administration reduces the severity of AHR, eosinophilia, and T cell infiltration associated with increased IL-18R expression, suggesting that IL-18 could promote resolution of local inflammation induced by an ongoing Th2 response [179]. Commensurate with this, adenoviral delivery of IL-18 in established ovalbumin-induced AHR reduces AHR, IL-4 production, mucus expression, and eosinophilia [180]. IL-18 similarly suppresses immune complex-mediated changes in lung vascular permeability, whereas IL-18 neutralization increases inflammatory parameters [181]. However, IL-18 increases eosinophil IL-8 release in vitro [182] and may also increase local eosinophil accumulation in vivo, in part via eotaxin release in the cockroach allergen-induced model [183]. These data together with the in vitro effects on Th2 maturation suggest that the precise effect of IL-18 may depend on the kinetics and nature of specific pulmonary antigen responses.

## Other inflammatory disease states

IL-18 expression has been described in a number of additional disease states. It is found together with a functional receptor in human atheroma tissues, predominantly in macrophages. IL-18 induces IL-6, IL-8, ICAM-1, and matrix metalloproteinase expression in vascular smooth muscle cells, endothelial cells, and macrophages [33]. Unexpectedly, IL-18 together with IL-12 also promoted IFN- $\gamma$  expression in smooth muscle cells.

Enhanced IL-18 expression has also been detected in acute and chronic hepatitis, systemic lupus erythematosus, psoriasis, and adult onset Still's disease [71, 72, 151, 184–187]. Very high serum levels of IL-18 are detected in the latter, which are equivalent to those detected in neoplastic and haemophagocytic syndromes in which cytokine dysregulation has been related to systemic clinical features such as fever and lymphadenopathy and with disease activity. However, there exist few clinical studies that clearly implicate IL-18 in disease pathogenesis, and many data remain circumstantial.

## CONCLUSION

Data generated thus far indicate that IL-18 contributes to host defense and to inflammation through synergism in a cascade of cytokines associated with innate responses, including IL-12 and IL-15. Important questions remain. In particular, the means whereby IL-18 synthesis is regulated, and subsequent release of cytokine is mediated are poorly understood. Similarly, regulation of IL-18 bioactivities in vivo in the context of high levels of IL-18BP and other native inhibitors requires clarification. Finally, the position of IL-18 in the functional hierarchy of proinflammatory cytokines in chronic inflammation is not fully resolved, although there is consensus that it plays a critical, early role. Nevertheless, IL-18 appears able to modulate inflammation at multiple checkpoints, acting not only on initiation and expansion of putative autoreactive Th/c1 responses but also via direct effects on multiple cellular targets, including macrophages, lymphocytes, and target host tissue cells—endothelial cells and fibroblasts. As such, it deserves consideration as a therapeutic target.

## ACKNOWLEDGMENTS

The authors receive funding support from the Arthritis Research Campaign (UK), the Wellcome Trust, and the Chief Scientist's Office, Scotland. Thanks to Professor Foo Y. Liew for critical discussions. The invaluable contributions of Dr. J. Young and Ms. A. Gilmour are acknowledged.

## REFERENCES

- Nakamura, K., Okamura, H., Wada, M., Nagata, K., Tamura, T. (1989) Endotoxin-induced serum factor that stimulates gamma interferon production. *Infect. Immun.* **57**, 590–595.
- Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature* **378**, 88–91.
- Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., Micallef, M., Fujii, M., et al. (1996) Cloning of the cDNA for human IFN-gamma-inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. *J. Immunol.* **156**, 4274–4279.
- Tone, M., Thompson, S. A., Tone, Y., Fairchild, P. J., Waldmann, H. (1997) Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. *J. Immunol.* **159**, 6156–6163.
- Puren, A. J., Fantuzzi, G., Dinarello, C. A. (1999) Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. *Proc. Natl. Acad. Sci. USA* **96**, 2256–2261.
- Kim, Y. M., Kang, H. S., Paik, S. G., Pyun, K. H., Anderson, K. L., Torbett, B. E., Choi, I. (1999) Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. *J. Immunol.* **163**, 2000–2007.
- Weisz, A., Kirchhoff, S., Levi, B. Z. (1994) IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters. *Int. Immunol.* **6**, 1125–1131.
- Sharf, R., Meraro, D., Azriel, A., Thornton, A. M., Ozato, K., Petricoin, E. F., Larner, A. C., Schaper, F., Hauser, H., Levi, B. Z. (1997) Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. *J. Biol. Chem.* **272**, 9785–9792.
- Shackelford, R., Adams, D. O., Johnson, S. P. (1995) IFN-gamma and lipopolysaccharide induce DNA binding of transcription factor PU.1 in murine tissue macrophages. *J. Immunol.* **154**, 1374–1382.
- Kim, Y. M., Im, J. Y., Han, S. H., Kang, H. S., Choi, I. (2000) IFN-gamma up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. *J. Immunol.* **165**, 3198–3205.
- Matsui, K., Yoshimoto, T., Tsutsui, H., Hyodo, Y., Hayashi, N., Hiroishi, K., Kawada, N., Okamura, H., Nakanishi, K., Higashino, K. (1997) Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. *J. Immunol.* **159**, 97–106.
- Stoll, S., Jonuleit, H., Schmitt, E., Muller, G., Yamauchi, H., Kurimoto, M., Knop, J., Enk, A. H. (1998) Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. *Eur. J. Immunol.* **28**, 3231–3239.
- Stoll, S., Muller, G., Kurimoto, M., Saloga, J., Tanimoto, T., Yamauchi, H., Okamura, H., Knop, J., Enk, A. H. (1997) Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. *J. Immunol.* **159**, 298–302.
- Udagawa, N., Horwood, N. J., Elliott, J., Mackay, A., Owens, J., Okamura, H., Kurimoto, M., Chambers, T. J., Martin, T. J., Gillespie, M. T. (1997) Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. *J. Exp. Med.* **185**, 1005–1012.
- Conti, B., Jahng, J. W., Tinti, C., Son, J. H., Joh, T. H. (1997) Induction of interferon-gamma inducing factor in the adrenal cortex. *J. Biol. Chem.* **272**, 2035–2037.
- Pizarro, T. T., Michie, M. H., Bentz, M., Woratanadham, J., Smith, M. F., Jr., Foley, E., Moskaluk, C. A., Bickston, S. J., Cominelli, F. (1999) IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. *J. Immunol.* **162**, 6829–6835.
- Prinz, M., Hanisch, U. K. (1999) Murine microglial cells produce and respond to interleukin-18. *J. Neurochem.* **72**, 2215–2218.
- Gracie, J. A., Forsey, R. J., Chan, W. L., Gilmour, A., Leung, B. P., Greer, M. R., Kennedy, K., Carter, R., Wei, X. Q., Xu, D., et al. (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. *J. Clin. Invest.* **104**, 1393–1401.
- Nakanishi, K., Yoshimoto, T., Tsutsui, H., Okamura, H. (2001) Interleukin-18 regulates both Th1 and Th2 responses. *Annu. Rev. Immunol.* **19**, 423–474.
- Ghayur, T., Banerjee, S., Hugunin, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., et al. (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. *Nature* **386**, 619–623.
- Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M. A., Hayashi, N., Higashino, K., Okamura, H., Nakanishi, K., et al. (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. *Science* **275**, 206–209.
- Fantuzzi, G., Puren, A. J., Harding, M. W., Livingston, D. J., Dinarello, C. A. (1998) Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. *Blood* **91**, 2118–2125.
- Melnikov, V. Y., Eceder, T., Fantuzzi, G., Siegmund, B., Lucia, M. S., Dinarello, C. A., Schrier, R. W., Edelstein, C. L. (2001) Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. *J. Clin. Invest.* **107**, 1145–1152.
- Pirhonen, J., Sareneva, T., Kurimoto, M., Julkunen, I., Matikainen, S. (1999) Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. *J. Immunol.* **162**, 7322–7329.

25. Sugawara, S., Uehara, A., Nochi, T., Yamaguchi, T., Ueda, H., Sugiyama, A., Hanzawa, K., Kumagai, K., Okamura, H., Takada, H. (2001) Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. *J. Immunol.* **167**, 6568–6575.
26. Akita, K., Ohtsuki, T., Nukada, Y., Tanimoto, T., Namba, M., Okura, T., Takakura-Yamamoto, R., Torigoe, K., Gu, Y., Su, M. S., et al. (1997) Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells. *J. Biol. Chem.* **272**, 26595–26603.
27. Torigoe, K., Ushio, S., Okura, T., Kobayashi, S., Tani, M., Kunikata, T., Murakami, T., Sanou, O., Kojima, H., Fujii, M., et al. (1997) Purification and characterization of the human interleukin-18 receptor. *J. Biol. Chem.* **272**, 25737–25742.
28. Hoshino, K., Tsutsui, H., Kawai, T., Takeda, K., Nakanishi, K., Takeda, Y., Akira, S. (1999) Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. *J. Immunol.* **162**, 5041–5044.
29. Parnet, P., Garka, K. E., Bonner, T. P., Dower, S. K., Sims, J. E. (1996) IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. *J. Biol. Chem.* **271**, 3967–3970.
30. Born, T. L., Thomassen, E., Bird, T. A., Sims, J. E. (1998) Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. *J. Biol. Chem.* **273**, 29445–29450.
31. Leung, B. P., Culshaw, S., Gracie, J. A., Hunter, D., Canetti, C. A., Campbell, C., Cunha, F., Liew, F. Y., McInnes, I. B. (2001) A role for IL-18 in neutrophil activation. *J. Immunol.* **167**, 2879–2886.
32. Hyodo, Y., Matsui, K., Hayashi, N., Tsutsui, H., Kashiwamura, S., Yamauchi, H., Hiroishi, K., Takeda, K., Tagawa, Y., Iwakura, Y., et al. (1999) IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. *J. Immunol.* **162**, 1662–1668.
33. Gerdes, N., Sukhova, G. K., Libby, P., Reynolds, R. S., Young, J. L., Schonbeck, U. (2002) Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. *J. Exp. Med.* **195**, 245–257.
34. Afkarian, M., Sedy, J. R., Yang, J., Jacobson, N. G., Cereb, N., Yang, S. Y., Murphy, T. L., Murphy, K. M. (2002) T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4(+) T cells. *Nat. Immunol.* **3**, 549–557.
35. Yoshimoto, T., Takeda, K., Tanaka, T., Ohkusu, K., Kashiwamura, S., Okamura, H., Akira, S., Nakanishi, K. (1998) IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. *J. Immunol.* **161**, 3400–3407.
36. Xu, D., Chan, W. L., Leung, B. P., Hunter, D., Schulz, K., Carter, R. W., McInnes, I. B., Robinson, J. H., Liew, F. Y. (1998) Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. *J. Exp. Med.* **188**, 1485–1492.
37. Smeltz, R. B., Chen, J., Hu-Li, J., Shevach, E. M. (2001) Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. *J. Exp. Med.* **194**, 143–153.
38. Wesche, H., Henzel, W. J., Shillinglaw, W., Li, S., Cao, Z. (1997) MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. *Immunity* **7**, 837–847.
39. Kanakaraj, P., Ngo, K., Wu, Y., Angulo, A., Ghazal, P., Harris, C. A., Siekierka, J. J., Peterson, P. A., Fung-Leung, W. P. (1999) Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. *J. Exp. Med.* **189**, 1129–1138.
40. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., Akira, S. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. *Immunity* **9**, 143–150.
41. Akira, S., Takeda, K., Kaisho, T. (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat. Immunol.* **2**, 675–680.
42. Seki, E., Tsutsui, H., Nakano, H., Tsuji, N., Hoshino, K., Adachi, O., Adachi, K., Futatsugi, S., Kuida, K., Takeuchi, O., et al. (2001) Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. *J. Immunol.* **166**, 2651–2657.
43. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., Goeddel, D. V. (1996) TRAF6 is a signal transducer for interleukin-1. *Nature* **383**, 443–446.
44. Kojima, H., Takeuchi, M., Ohta, T., Nishida, Y., Arai, N., Ikeda, M., Ikegami, H., Kurimoto, M. (1998) Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. *Biochem. Biophys. Res. Commun.* **244**, 183–186.
45. Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley, S. B., Menon, S., Kastelein, R., Bazan, F., et al. (1997) IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. *Immunity* **7**, 571–581.
46. Matsumoto, S., Tsuji-Takayama, K., Aizawa, Y., Koide, K., Takeuchi, M., Ohta, T., Kurimoto, M. (1997) Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. *Biochem. Biophys. Res. Commun.* **234**, 454–457.
47. Kojima, H., Aizawa, Y., Yanai, Y., Nagaoka, K., Takeuchi, M., Ohta, T., Ikegami, H., Ikeda, M., Kurimoto, M. (1999) An essential role for NF-kappa B in IL-18-induced IFN-gamma expression in KG-1 cells. *J. Immunol.* **162**, 5063–5069.
48. Kalina, U., Kauschat, D., Koyama, N., Nuernberger, H., Ballas, K., Koschmieder, S., Bug, G., Hofmann, W. K., Hoelzer, D., Ottmann, O. G. (2000) IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. *J. Immunol.* **165**, 1307–1313.
49. Yang, J., Zhu, H., Murphy, T. L., Ouyang, W., Murphy, K. M. (2001) IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. *Nat. Immunol.* **2**, 157–164.
50. Gerwins, P., Blank, J. L., Johnson, G. L. (1997) Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. *J. Biol. Chem.* **272**, 8288–8295.
51. Takekawa, M., Saito, H. (1998) A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. *Cell* **95**, 521–530.
52. Shimoda, K., Tsutsui, H., Aoki, K., Kato, K., Matsuda, T., Numata, A., Takase, K., Yamamoto, T., Nukina, H., Hoshino, T., et al. (2002) Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. *Blood* **99**, 2094–2099.
53. Barbulescu, K., Becker, C., Schlaak, J. F., Schmitt, E., Meyer zum Buschenfelde, K. H., Neurath, M. F. (1998) IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. *J. Immunol.* **160**, 3642–3647.
54. Nakahira, M., Ahn, H. J., Park, W. R., Gao, P., Tomura, M., Park, C. S., Hamaoka, T., Ohta, T., Kurimoto, M., Fujiwara, H. (2002) Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. *J. Immunol.* **168**, 1146–1153.
55. Morel, J. C., Park, C. C., Woods, J. M., Koch, A. E. (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. *J. Biol. Chem.* **276**, 37069–37075.
56. Micallef, M. J., Ohtsuki, T., Kohno, K., Tanabe, F., Ushio, S., Namba, M., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., et al. (1996) Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. *Eur. J. Immunol.* **26**, 1647–1651.
57. Dao, T., Mehal, W. Z., Crispe, I. N. (1998) IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. *J. Immunol.* **161**, 2217–2222.
58. Dao, T., Ohashi, K., Kayano, T., Kurimoto, M., Okamura, H. (1996) Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. *Cell. Immunol.* **173**, 230–235.
59. Tsutsui, H., Nakanishi, K., Matsui, K., Higashino, K., Okamura, H., Miyazawa, Y., Kaneda, K. (1996) IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. *J. Immunol.* **157**, 3967–3973.
60. Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., Akira, S. (1998) Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* **8**, 383–390.
61. Hoshino, T., Wiltrot, R. H., Young, H. A. (1999) IL-18 is a potent inducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. *J. Immunol.* **162**, 5070–5077.
62. Hoshino, T., Yagita, H., Ortaldo, J. R., Wiltrot, R. H., Young, H. A. (2000) In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. *Eur. J. Immunol.* **30**, 1998–2006.



63. Yoshimoto, T., Mizutani, H., Tsutsui, H., Noben-Trauth, N., Yamanaka, K., Tanaka, M., Izumi, S., Okamura, H., Paul, W. E., Nakanishi, K. (2000) IL-18 induction of IgE: dependence on CD4<sup>+</sup> T cells, IL-4 and STAT6. *Nat. Immunol.* **1**, 132–137.
64. Xu, D., Trajkovic, V., Hunter, D., Leung, B. P., Schulz, K., Gracie, J. A., McInnes, I. B., Liew, F. Y. (2000) IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. *Eur. J. Immunol.* **30**, 3147–3156.
65. Yoshimoto, T., Tsutsui, H., Tominaga, K., Hoshino, K., Okamura, H., Akira, S., Paul, W. E., Nakanishi, K. (1999) IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. *Proc. Natl. Acad. Sci. USA* **96**, 13962–13966.
66. Munder, M., Mallo, M., Eichmann, K., Modolell, M. (1998) Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. *J. Exp. Med.* **187**, 2103–2108.
67. Fukao, T., Matsuda, S., Koyasu, S. (2000) Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. *J. Immunol.* **164**, 64–71.
68. Netea, M. G., Kullberg, B. J., Verschuere, I., Van Der Meer, J. W. (2000) Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. *Eur. J. Immunol.* **30**, 3057–3060.
69. Olee, T., Hashimoto, S., Quach, J., Lotz, M. (1999) IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. *J. Immunol.* **162**, 1096–1100.
70. Horwood, N. J., Udagawa, N., Elliott, J., Grail, D., Okamura, H., Kurimoto, M., Dunn, A. R., Martin, T., Gillespie, M. T. (1998) Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. *J. Clin. Invest.* **101**, 595–603.
71. Mee, J. B., Alam, Y., Groves, R. W. (2000) Human keratinocytes constitutively produce but do not process interleukin-18. *Br. J. Dermatol.* **143**, 330–336.
72. Naik, S. M., Cannon, G., Burbach, G. J., Singh, S. R., Swerlick, R. A., Wilcox, J. N., Ansel, J. C., Caughman, S. W. (1999) Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. *J. Invest. Dermatol.* **113**, 766–772.
73. Cumberbatch, M., Dearman, R. J., Antonopoulos, C., Groves, R. W., Kimber, I. (2001) Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism. *Immunology* **102**, 323–330.
74. Novick, D., Kim, S. H., Fantuzzi, G., Reznikov, L. L., Dinarello, C. A., Rubinstein, M. (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. *Immunity* **10**, 127–136.
75. Aizawa, Y., Akita, K., Taniai, M., Torigoe, K., Mori, T., Nishida, Y., Ushio, S., Nukada, Y., Tanimoto, T., Ikegami, H., et al. (1999) Cloning and expression of interleukin-18 binding protein. *FEBS Lett.* **445**, 338–342.
76. Reznikov, L. L., Kim, S. H., Westcott, J. Y., Frishman, J., Fantuzzi, G., Novick, D., Rubinstein, M., Dinarello, C. A. (2000) IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. *Proc. Natl. Acad. Sci. USA* **97**, 2174–2179.
77. Paulukat, J., Bosmann, M., Nold, M., Garkisch, S., Kampfer, H., Frank, S., Raedle, J., Zeuzem, S., Pfeilschifter, J., Muhl, H. (2001) Expression and release of IL-18 binding protein in response to IFN-gamma. *J. Immunol.* **167**, 7038–7043.
78. Novick, D., Schwartzburd, B., Pinkus, R., Suissa, D., Belzer, I., Stoeber, Z., Keane, W. F., Chvatchko, Y., Kim, S. H., Fantuzzi, G., et al. (2001) A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. *Cytokine* **14**, 334–342.
79. Corbaz, A., ten Hove, T., Herren, S., Graber, P., Schwartzburd, B., Belzer, I., Harrison, J., Plitz, T., Kosco-Vilbois, M. H., Kim, S. H., et al. (2002) IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. *J. Immunol.* **168**, 3608–3616.
80. Kim, S. H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., Dinarello, C. A. (2000) Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. *Proc. Natl. Acad. Sci. USA* **97**, 1190–1195.
81. Born, T. L., Morrison, L. A., Esteban, D. J., VandenBos, T., Thebeau, L. G., Chen, N., Spriggs, M. K., Sims, J. E., Buller, R. M. (2000) A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. *J. Immunol.* **164**, 3246–3254.
82. Xiang, Y., Moss, B. (1999) IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. *Proc. Natl. Acad. Sci. USA* **96**, 11537–11542.
83. Pan, G., Risser, P., Mao, W., Baldwin, D. T., Zhong, A. W., Filvaroff, E., Yansura, D., Lewis, L., Eigenbrot, C., Henzel, W. J., et al. (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rr. *Cytokine* **13**, 1–7.
84. Nakamura, K., Okamura, H., Nagata, K., Komatsu, T., Tamura, T. (1993) Purification of a factor which provides a costimulatory signal for gamma interferon production. *Infect. Immun.* **61**, 64–70.
85. Wei, X. Q., Leung, B. P., Niedbala, W., Piedrafita, D., Feng, G. J., Sweet, M., Dobbie, L., Smith, A. J., Liew, F. Y. (1999) Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. *J. Immunol.* **163**, 2821–2828.
86. Ohkusu, K., Yoshimoto, T., Takeda, K., Ogura, T., Kashiwamura, S., Iwakura, Y., Akira, S., Okamura, H., Nakanishi, K. (2000) Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. *Infect. Immun.* **68**, 2449–2456.
87. Kawakami, K., Koguchi, Y., Qureshi, M. H., Miyazato, A., Yara, S., Kinjo, Y., Iwakura, Y., Takeda, K., Akira, S., Kurimoto, M., et al. (2000) IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. *J. Immunol.* **165**, 941–947.
88. Lauw, F. N., Branger, J., Florquin, S., Speelman, P., van Deventer, S. J., Akira, S., van der Poll, T. (2002) IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. *J. Immunol.* **168**, 372–378.
89. Singh, R. P., Kashiwamura, S., Rao, P., Okamura, H., Mukherjee, A., Chauhan, V. S. (2002) The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. *J. Immunol.* **168**, 4674–4681.
90. Sugawara, I., Yamada, H., Kaneko, H., Mizuno, S., Takeda, K., Akira, S. (1999) Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. *Infect. Immun.* **67**, 2585–2589.
91. Sakao, Y., Takeda, K., Tsutsui, H., Kaisho, T., Nomura, F., Okamura, H., Nakanishi, K., Akira, S. (1999) IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. *Int. Immunol.* **11**, 471–480.
92. Wei, X., Leung, B. P., Arthur, H. M., McInnes, I. B., Liew, F. Y. (2001) Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. *J. Immunol.* **166**, 517–521.
93. Kanai, T., Watanabe, M., Okazawa, A., Sato, T., Yamazaki, M., Okamoto, S., Ishii, H., Totsuka, T., Iiyama, R., Okamoto, R., et al. (2001) Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. *Gastroenterology* **121**, 875–888.
94. Nomura, T., Kawamura, I., Tsuchiya, K., Kohda, C., Baba, H., Ito, Y., Kimoto, T., Watanabe, I., Mitsuyama, M. (2002) Essential role of interleukin-12 (IL-12) and IL-18 for gamma interferon production induced by listeriolysin O in mouse spleen cells. *Infect. Immun.* **70**, 1049–1055.
95. Shi, F. D., Takeda, K., Akira, S., Sarvetnick, N., Ljunggren, H. G. (2000) IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. *J. Immunol.* **165**, 3099–3104.
96. Hochholzer, P., Lipford, G. B., Wagner, H., Pfeffer, K., Heeg, K. (2000) Role of interleukin-18 (IL-18) during lethal shock: decreased lipopolysaccharide sensitivity but normal superantigen reaction in IL-18-deficient mice. *Infect. Immun.* **68**, 3502–3508.
97. Helmby, H., Takeda, K., Akira, S., Grencis, R. K. (2001) Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. *J. Exp. Med.* **194**, 355–364.
98. Mori, I., Hossain, M. J., Takeda, K., Okamura, H., Imai, Y., Kohsaka, S., Kimura, Y. (2001) Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent influenza A virus infection. *Virology* **287**, 163–170.
99. Kinjo, Y., Kawakami, K., Uezu, K., Yara, S., Miyagi, K., Koguchi, Y., Hoshino, T., Okamoto, M., Kawase, Y., Yokota, K., et al. (2002) Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. *J. Immunol.* **169**, 323–329.
100. Kobayashi, K., Nakata, N., Kai, M., Kasama, T., Hanyuda, Y., Hatano, Y. (1997) Decreased expression of cytokines that induce type 1 helper T cell/interferon-gamma responses in genetically susceptible mice infected with Mycobacterium avium. *Clin. Immunol. Immunopathol.* **85**, 112–116.

101. Vankayalapati, R., Wizel, B., Weis, S. E., Samten, B., Girard, W. M., Barnes, P. F. (2000) Production of interleukin-18 in human tuberculosis. *J. Infect. Dis.* **182**, 234–239.
102. Yamada, G., Shijubo, N., Shigehara, K., Okamura, H., Kurimoto, M., Abe, S. (2000) Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. *Am. J. Respir. Crit. Care Med.* **161**, 1786–1789.
103. Garcia, V. E., Uyemura, K., Sieling, P. A., Ochoa, M. T., Morita, C. T., Okamura, H., Kurimoto, M., Rea, T. H., Modlin, R. L. (1999) IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. *J. Immunol.* **162**, 6114–6121.
104. Mastroeni, P., Clare, S., Khan, S., Harrison, J. A., Hormaeche, C. E., Okamura, H., Kurimoto, M., Dougan, G. (1999) Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent *Salmonella typhimurium*. *Infect. Immun.* **67**, 478–483.
105. Bohn, E., Sing, A., Zumbihl, R., Bielfeldt, C., Okamura, H., Kurimoto, M., Heeseemann, J., Autenrieth, I. B. (1998) IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. *J. Immunol.* **160**, 299–307.
106. Lu, H., Yang, X., Takeda, K., Zhang, D., Fan, Y., Luo, M., Shen, C., Wang, S., Akira, S., Brunham, R. C. (2000) Chlamydia trachomatis mouse pneumonitis lung infection in IL-18 and IL-12 knockout mice: IL-12 is dominant over IL-18 for protective immunity. *Mol. Med.* **6**, 604–612.
107. Sansonetti, P. J., Phalipon, A., Arondel, J., Thirumalai, K., Banerjee, S., Akira, S., Takeda, K., Zychlinsky, A. (2000) Caspase-1 activation of IL-1beta and IL-18 are essential for *Shigella flexneri*-induced inflammation. *Immunity* **12**, 581–590.
108. Fujioka, N., Akazawa, R., Ohashi, K., Fujii, M., Ikeda, M., Kurimoto, M. (1999) Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. *J. Virol.* **73**, 2401–2409.
109. Tanaka-Kataoka, M., Kunikata, T., Takayama, S., Iwaki, K., Ohashi, K., Ikeda, M., Kurimoto, M. (1999) In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. *Cytokine* **11**, 593–599.
110. Cho, Y. S., Kang, J. W., Cho, M., Cho, C. W., Lee, S., Choe, Y. K., Kim, Y., Choi, I., Park, S. N., Kim, S., et al. (2001) Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. *FEBS Lett.* **501**, 139–145.
111. Shapiro, L., Puren, A. J., Barton, H. A., Novick, D., Peskind, R. L., Shenkar, R., Gu, Y., Su, M. S., Dinarello, C. A. (1998) Interleukin 18 stimulates HIV type 1 in monocytic cells. *Proc. Natl. Acad. Sci. USA* **95**, 12550–12555.
112. Choi, H. J., Dinarello, C. A., Shapiro, L. (2001) Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells. *J. Infect. Dis.* **184**, 560–568.
113. Billaut-Mulot, O., Idziorek, T., Ban, E., Kremer, L., Dupre, L., Loyens, M., Riveau, G., Loch, C., Capron, A., Bahr, G. M. (2000) Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine. *Vaccine* **19**, 95–102.
114. Hanlon, L., Argyle, D., Bain, D., Nicolson, L., Dunham, S., Golder, M. C., McDonald, M., McGillivray, C., Jarrett, O., Neil, J. C., et al. (2001) Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. *J. Virol.* **75**, 8424–8433.
115. Mayne, M., Cheadle, C., Soldan, S. S., Cermelli, C., Yamano, Y., Akhyani, N., Nagel, J. E., Taub, D. D., Becker, K. G., Jacobson, S. (2001) Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. *J. Virol.* **75**, 11641–11650.
116. Arena, A., Iannello, D., Gazzara, D., Speranza, A., Bonina, L., Mastroeni, P. (2001) Role of interleukin-18 in peripheral blood mononuclear cells infected with human herpes virus type 6. *Intervirology* **44**, 250–254.
117. Yoshida, A., Kand, T., Tanaka, T., Yokoyama, T., Kurimoto, M., Tamura, J., Kobayashi, I. (2002) Interleukin-18 reduces expression of cardiac tumor necrosis factor-alpha and atrial natriuretic peptide in a murine model of viral myocarditis. *Life Sci.* **70**, 1225–1234.
118. Kanda, T., Tanaka, T., Sekiguchi, K., Seta, Y., Kurimoto, M., Wilson McManus, J. E., Nagai, R., Yang, D., McManus, B. M., Kobayashi, I. (2000) Effect of interleukin-18 on viral myocarditis: enhancement of interferon-gamma and natural killer cell activity. *J. Mol. Cell. Cardiol.* **32**, 2163–2171.
119. Gluck, B., Schmidtke, M., Merkle, I., Stelzner, A., Gemsa, D. (2001) Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. *J. Mol. Cell. Cardiol.* **33**, 1615–1626.
120. Kobayashi, K., Kai, M., Gidoh, M., Nakata, N., Endoh, M., Singh, R. P., Kasama, T., Saito, H. (1998) The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental *Mycobacterium leprae* infection in mice. *Clin. Immunol. Immunopathol.* **88**, 226–231.
121. Song, C. H., Kim, H. J., Park, J. K., Lim, J. H., Kim, U. O., Kim, J. S., Paik, T. H., Kim, K. J., Suhr, J. W., Jo, E. K. (2000) Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. *Infect. Immun.* **68**, 4477–4484.
122. Xing, Z., Zganiacz, A., Wang, J., Divangahi, M., Nawaz, F. (2000) IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes. *J. Immunol.* **164**, 2575–2584.
123. Pien, G. C., Satoskar, A. R., Takeda, K., Akira, S., Biron, C. A. (2000) Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection. *J. Immunol.* **165**, 4787–4791.
124. Yao, L., Setsuda, J., Sgadari, C., Cherney, B., Tosato, G. (2001) Interleukin-18 expression induced by Epstein-Barr virus-infected cells. *J. Leukoc. Biol.* **69**, 779–784.
125. Okada, H., Sato, T. A., Katayama, A., Higuchi, K., Shichijo, K., Tsuchiya, T., Takayama, N., Takeuchi, Y., Abe, T., Okabe, N., et al. (2001) Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. *Arch. Virol.* **146**, 859–874.
126. Sareneva, T., Matikainen, S., Kurimoto, M., Julkunen, I. (1998) Influenza A virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells. *J. Immunol.* **160**, 6032–6038.
127. Tovey, M. G., Meritet, J. F., Guymarho, J., Maury, C. (1999) Mucosal cytokine therapy: marked antiviral and antitumor activity. *J. Interferon Cytokine Res.* **19**, 911–921.
128. Klein, S. A., Klebba, C., Kauschat, D., Pape, M., Ozmen, L., Hoelzer, D., Ottmann, O. G., Kalina, U. (2000) Interleukin-18 stimulates HIV-1 replication in a T-cell line. *Eur. Cytokine Netw.* **11**, 47–52.
129. Hensley, L. E., Young, H. A., Jahrling, P. B., Geisbert, T. W. (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. *Immunol. Lett.* **80**, 169–179.
130. Qureshi, M. H., Zhang, T., Koguchi, Y., Nakashima, K., Okamura, H., Kurimoto, M., Kawakami, K. (1999) Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with *Cryptococcus neoformans*. *Eur. J. Immunol.* **29**, 643–649.
131. Zhang, T., Kawakami, K., Qureshi, M. H., Okamura, H., Kurimoto, M., Saito, A. (1997) Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against *Cryptococcus neoformans* through production of gamma interferon by natural killer cells. *Infect. Immun.* **65**, 3594–3599.
132. Blease, K., Kunkel, S. L., Hogaboam, C. M. (2001) IL-18 modulates chronic fungal asthma in a murine model; putative involvement of Toll-like receptor-2. *Inflamm. Res.* **50**, 552–560.
133. Mencacci, A., Bacci, A., Cenci, E., Montagnoli, C., Fiorucci, S., Casagrande, A., Flavell, R. A., Bistoni, F., Romani, L. (2000) Interleukin 18 restores defective Th1 immunity to *Candida albicans* in caspase 1-deficient mice. *Infect. Immun.* **68**, 5126–5131.
134. Monteforte, G. M., Takeda, K., Rodriguez-Sosa, M., Akira, S., David, J. R., Satoskar, A. R. (2000) Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous *Leishmania major* infection. *J. Immunol.* **164**, 5890–5893.
135. Meyer Zum Buschenfelde, C., Cramer, S., Trumpfheller, C., Fleischer, B., Frosch, S. (1997) Trypanosoma cruzi induces strong IL-12 and IL-18 gene expression in vivo: correlation with interferon-gamma (IFN-gamma) production. *Clin. Exp. Immunol.* **110**, 378–385.
136. Antunez, M. I., Cardoni, R. L. (2001) Early IFN-gamma production is related to the presence of interleukin (IL)-18 and the absence of IL-13 in experimental *Trypanosoma cruzi* infections. *Immunol. Lett.* **79**, 189–196.
137. Okamura, H., Tsutsui, H., Kashiwamura, S., Yoshimoto, T., Nakanishi, K. (1998) Interleukin-18: a novel cytokine that augments both innate and acquired immunity. *Adv. Immunol.* **70**, 281–312.
138. Torre, D., Giola, M., Speranza, F., Matteelli, A., Basilico, C., Biondi, G. (2001) Serum levels of interleukin-18 in patients with uncomplicated *Plasmodium falciparum* malaria. *Eur. Cytokine Netw.* **12**, 361–364.
139. Kawakami, K., Qureshi, M. H., Zhang, T., Okamura, H., Kurimoto, M., Saito, A. (1997) IL-18 protects mice against pulmonary and dissemi-

- nated infection with *Cryptococcus neoformans* by inducing IFN-gamma production. *J. Immunol.* **159**, 5528–5534.
140. Brummer, E. (1998) Human defenses against *Cryptococcus neoformans*: an update. *Mycopathologia* **143**, 121–125.
  141. Sher, A., Gazzinelli, R. T., Oswald, I. P., Clerici, M., Kullberg, M., Pearce, E. J., Berzofsky, J. A., Mosmann, T. R., James, S. L., Morse III, H. C. (1992) Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. *Immunol. Rev.* **127**, 183–204.
  142. Reiner, S. L., Locksley, R. M. (1995) The regulation of immunity to *Leishmania major*. *Annu. Rev. Immunol.* **13**, 151–177.
  143. Cai, G., Kastelein, R., Hunter, C. A. (2000) Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to *Toxoplasma gondii*. *Infect. Immun.* **68**, 6932–6938.
  144. Yap, G. S., Ortmann, R., Shevach, E., Sher, A. (2001) A heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to *Toxoplasma gondii* and rescue by IL-18 treatment. *J. Immunol.* **166**, 5720–5725.
  145. Mordue, D. G., Monroy, F., La Regina, M., Dinarello, C. A., Sibley, L. D. (2001) Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. *J. Immunol.* **167**, 4574–4584.
  146. Dinarello, C. A. (1999) IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. *J. Allergy Clin. Immunol.* **103**, 11–24.
  147. Yamamura, M., Kawashima, M., Tani, M., Yamauchi, H., Tanimoto, T., Kurimoto, M., Morita, Y., Ohmoto, Y., Makino, H. (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. *Arthritis Rheum.* **44**, 275–285.
  148. Tanaka, M., Harigai, M., Kawaguchi, Y., Ohta, S., Sugiura, T., Takagi, K., Ohsako-Higami, S., Fukasawa, C., Hara, M., Kamatani, N. (2001) Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. *J. Rheumatol.* **28**, 1779–1787.
  149. Moller, B., Kukoc-Zivojnov, N., Kessler, U., Rehart, S., Kaltwasser, J. P., Hoelzer, D., Kalina, U., Ottmann, O. G. (2001) Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. *Rheumatology* **40**, 302–309.
  150. Moller, B., Kessler, U., Rehart, S., Kalina, U., Ottmann, O. G., Peter Kaltwasser, J., Hoelzer, D., Kukoc-Zivojnov, N. (2002) Expression of interleukin-18 receptor in fibroblast-like synoviocytes. *Arthritis Res.* **4**, 139–144.
  151. Kawashima, M., Yamamura, M., Tani, M., Yamauchi, H., Tanimoto, T., Kurimoto, M., Miyawaki, S., Amano, T., Takeuchi, T., Makino, H. (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. *Arthritis Rheum.* **44**, 550–560.
  152. Lubberts, E., Joosten, L. A., Oppers, B., van den Berselaar, L., Coenen-de Roo, C. J., Kolls, J. K., Schwarzenberger, P., van de Loo, F. A., van den Berg, W. B., Helsen, M. M., et al. (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. *J. Immunol.* **167**, 1004–1013.
  153. Morel, J. C., Park, C. C., Kumar, P., Koch, A. E. (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF-kappaB activation. *Lab. Invest.* **81**, 1371–1383.
  154. Park, C. C., Morel, J. C., Amin, M. A., Connors, M. A., Harlow, L. A., Koch, A. E. (2001) Evidence of IL-18 as a novel angiogenic mediator. *J. Immunol.* **167**, 1644–1653.
  155. Leung, B. P., McInnes, I. B., Esfandiari, E., Wei, X. Q., Liew, F. Y. (2000) Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. *J. Immunol.* **164**, 6495–6502.
  156. Plater-Zyberk, C., Joosten, L. A., Helsen, M. M., Sattouet-Roche, P., Siegfried, C., Alouani, S., van De Loo, F. A., Graber, P., Aloni, S., Cirillo, R., et al. (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. *J. Clin. Invest.* **108**, 1825–1832.
  157. Rothe, H., Jenkins, N. A., Copeland, N. G., Kolb, H. (1997) Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. *J. Clin. Invest.* **99**, 469–474.
  158. Andre-Schmutz, I., Hindelang, C., Benoist, C., Mathis, D. (1999) Cellular and molecular changes accompanying the progression from insulinitis to diabetes. *Eur. J. Immunol.* **29**, 245–255.
  159. Rothe, H., Hausmann, A., Casteels, K., Okamura, H., Kurimoto, M., Burkart, V., Mathieu, C., Kolb, H. (1999) IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulinitis. *J. Immunol.* **163**, 1230–1236.
  160. Nicoletti, F., Conget, I., Di Marco, R., Speciale, A. M., Morinigo, R., Bendtzen, K., Gomis, R. (2001) Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. *Diabetologia* **44**, 309–311.
  161. Steinman, L. (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. *Cell* **85**, 299–302.
  162. Wildbaum, G., Youssef, S., Grabie, N., Karin, N. (1998) Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. *J. Immunol.* **161**, 6368–6374.
  163. Jander, S., Stoll, G. (1998) Differential induction of interleukin-12, interleukin-18, and interleukin-1beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. *J. Neuroimmunol.* **91**, 93–99.
  164. Balashov, K. E., Rottman, J. B., Weiner, H. L., Hancock, W. W. (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. *Proc. Natl. Acad. Sci. USA* **96**, 6873–6878.
  165. Furlan, R., Martino, G., Galbiati, F., Poliani, P. L., Smirolto, S., Bergami, A., Desina, G., Comi, G., Flavell, R., Su, M. S., et al. (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. *J. Immunol.* **163**, 2403–2409.
  166. Furlan, R., Filippi, M., Bergami, A., Rocca, M. A., Martinelli, V., Poliani, P. L., Grimaldi, L. M., Desina, G., Comi, G., Martino, G. (1999) Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. *J. Neurol. Neurosurg. Psychiatry* **67**, 785–788.
  167. Monteleone, G., Trapasso, F., Parrello, T., Biancone, L., Stella, A., Iuliano, R., Luzzo, F., Fusco, A., Pallone, F. (1999) Bioactive IL-18 expression is up-regulated in Crohn's disease. *J. Immunol.* **163**, 143–147.
  168. Kanai, T., Watanabe, M., Okazawa, A., Sato, T., Hibi, T. (2001) Interleukin-18 and Crohn's disease. *Digestion* **63**, Suppl 1, 37–42.
  169. Furuya, D., Yagihashi, A., Komatsu, M., Masashi, N., Tsuji, N., Kobayashi, D., Watanabe, N. (2002) Serum interleukin-18 concentrations in patients with inflammatory bowel disease. *J. Immunother.* **25**, Suppl 1, S65–S67.
  170. Chikano, S., Sawada, K., Shimoyama, T., Kashiwamura, S. I., Sugihara, A., Sekikawa, K., Terada, N., Nakanishi, K., Okamura, H. (2000) IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. *Gut* **47**, 779–786.
  171. Siegmund, B., Lehr, H. A., Fantuzzi, G., Dinarello, C. A. (2001) IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. *Proc. Natl. Acad. Sci. USA* **98**, 13249–13254.
  172. Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H. A., Hartmann, G., Dinarello, C. A., Endres, S., Eigler, A. (2001) Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **281**, R1264–R1273.
  173. Sivakumar, P. V., Westrich, G. M., Kanaly, S., Garka, K., Born, T. L., Derry, J. M., Viney, J. L. (2002) Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. *Gut* **50**, 812–820.
  174. Camoglio, L., Juffermans, N. P., Peppelenbosch, M., te Velde, A. A., ten Kate, F. J., van Deventer, S. J., Kopf, M. (2002) Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. *Eur. J. Immunol.* **32**, 261–269.
  175. Wirtz, S., Becker, C., Blumberg, R., Galle, P. R., Neurath, M. F. (2002) Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. *J. Immunol.* **168**, 411–420.
  176. Shigehara, K., Shijubo, N., Ohmichi, M., Yamada, G., Takahashi, R., Okamura, H., Kurimoto, M., Hiraga, Y., Tatsuno, T., Abe, S., et al. (2000) Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. *Am. J. Respir. Crit. Care Med.* **162**, 1979–1982.
  177. Ho, L. P., Davis, M., Denison, A., Wood, F. T., Greening, A. P. (2002) Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. *Chest* **121**, 1421–1426.
  178. Kodama, T., Matsuyama, T., Kuribayashi, K., Nishioka, Y., Sugita, M., Akira, S., Nakanishi, K., Okamura, H. (2000) IL-18 deficiency selectively enhances allergen-induced eosinophilia in mice. *J. Allergy Clin. Immunol.* **105**, 45–53.
  179. Kuribayashi, K., Kodama, T., Okamura, H., Sugita, M., Matsuyama, T. (2002) Effects of post-inhalation treatment with interleukin-12 on airway hyper-reactivity, eosinophilia interleukin-18 receptor expression in a mouse model of asthma. *Clin. Exp. Allergy* **32**, 641–649.
  180. Walter, D. M., Wong, C. P., DeKruyff, R. H., Berry, G. J., Levy, S., Umetsu, D. T. (2001) IL-18 gene transfer by adenovirus prevents the

- development of and reverses established allergen-induced airway hyperreactivity. *J. Immunol.* **166**, 6392–6398.
181. Jordan, J. A., Guo, R. F., Yun, E. C., Sarma, V., Warner, R. L., Crouch, L. D., Senaldi, G., Ulich, T. R., Ward, P. A. (2001) Role of IL-18 in acute lung inflammation. *J. Immunol.* **167**, 7060–7068.
182. Wang, W., Tanaka, T., Okamura, H., Sugita, M., Higa, S., Kishimoto, T., Suemura, M. (2001) Interleukin-18 enhances the production of interleukin-8 by eosinophils. *Eur. J. Immunol.* **31**, 1010–1016.
183. Campbell, E., Kunkel, S. L., Strieter, R. M., Lukacs, N. W. (2000) Differential roles of IL-18 in allergic airway disease: induction of eotaxin by resident cell populations exacerbates eosinophil accumulation. *J. Immunol.* **164**, 1096–1102.
184. Yumoto, E., Higashi, T., Nouse, K., Nakatsukasa, H., Fujiwara, K., Hanafusa, T., Yumoto, Y., Tanimoto, T., Kurimoto, M., Tanaka, N., et al. (2002) Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. *J. Gastroenterol. Hepatol.* **17**, 285–294.
185. Urushihara, N., Iwagaki, H., Yagi, T., Kohka, H., Kobashi, K., Morimoto, Y., Yoshino, T., Tanimoto, T., Kurimoto, M., Tanaka, N. (2000) Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. *J. Pediatr. Surg.* **35**, 446–449.
186. Wong, C. K., Li, E. K., Ho, C. Y., Lam, C. W. (2000) Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. *Rheumatology* **39**, 1073–1081.
187. Kawaguchi, Y., Terajima, H., Harigai, M., Hara, M., Kamatani, N. (2001) Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. *Arthritis Rheum.* **44**, 1716–1717.